ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pharmacoepidemiology"

  • Abstract Number: 2021 • ACR Convergence 2024

    The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies

    Natalie McCormick1, Chio Yokose2, Leo Lu3, Deborah Wexler1, J. Antonio Avina-Zubieta4, Mary A. De Vera5, saiajay chigurupati1, Kiara Tan1, Chixiang Chen6, Rozalina McCoy6, Gary Curhan7 and Hyon K. Choi8, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 5University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, 6University of Maryland, School of Medicine, Baltimore, MD, 7Brigham and Women's Hospital, Boston, MA, 8Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
  • Abstract Number: 0913 • ACR Convergence 2024

    The Association Between PTPN2 and Leukopenia in New Users of Azathioprine

    Puran Nepal1, Laura L. Daniel2, Jacy Zanussi2, Alyson L. Dickson3, Wei-Qi Wei3, Adriana M. Hung4, Nancy J. Cox3, Vivian K. Kawai3, Jonathan D. Mosley3, C. Michael Stein3, QiPing Feng3, Ge Liu3, Ran Tao3 and Cecilia P. Chung2, 1Vanderbilt University Medical Center, Vanderbilt, TN, 2University of Miami, Miami, FL, 3Vanderbilt University Medical Center, Nashville, TN, 4Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Leukopenia is a common dose-dependent side effect of azathioprine and often results in discontinuation of the drug. Variants in TPMT and NUDT15 have been…
  • Abstract Number: 2022 • ACR Convergence 2024

    Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies

    Natalie McCormick1, Chio Yokose2, Leo Lu3, Sharan Rai1, Gregory Challener1 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
  • Abstract Number: 0914 • ACR Convergence 2024

    RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine

    Shailja C. Shah1, Tyler S. Reese2, Laura L. Daniel3, Puran Nepal4, Jacy Zanussi3, Alyson L. Dickson2, Ran Tao2, Adriana M. Hung5, Wei-Qi Wei2, C. Michael Stein2, QiPing Feng2 and Cecilia P. Chung3, 1University of California, San Diego, San Diego, CA, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Miami, Miami, FL, 4Vanderbilt University Medical Center, Vanderbilt, TN, 5Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Pancreatitis is a rare, but potentially life-threatening adverse event associated with the use of azathioprine. Prior studies have found an association between the HLA…
  • Abstract Number: 2091 • ACR Convergence 2024

    Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic

    Derek Ochi1, Dagoberto Pina2, Manmeet Kaur3, Jeffery Fine4, Daniel Black5 and Barton Wise6, 1Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Sacramento, CA, 2School of Medicine, University of California Davis, Sacramento, CA, 3Division of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, CA, 4Department of Public Health Sciences, University of California Davis, Sacramento, CA, 5Innovation Technology - Data Center of Excellence, University of California Davis, Sacramento, CA, 6Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis and Department of Orthopaedic Surgery, University of California Davis, Sacramneto, CA

    Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…
  • Abstract Number: 0989 • ACR Convergence 2024

    Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis

    Mark Gibson1, Benjamin Zuckerman2, Maryam Adas1, Mark Russell3, Katie Bechman1 and James Galloway4, 1King's College London, London, United Kingdom, 2King's College London, London, England, United Kingdom, 3King's College London, London, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
  • Abstract Number: 2479 • ACR Convergence 2024

    Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices

    Michael E Wechsler1, Anna Kovalszki2, Jared Silver3, Brian Stone4, Lior Seluk5, Lynn Huynh6, Wilson da Costa Junior6, Mingchen Ye6, Jeremiah Hwee7, Mei Sheng Duh6, William McCann4 and Amy G. Edgecomb8, 1Department of Medicine, National Jewish Health, Denver, CO, 2Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 3US Medical Affairs - Respiratory, GSK, Durham, 4Allergy Partners, Asheville, NC, 5Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, 6Analysis Group, Boston, MA, 7Value Evidence and Outcomes, GSK, Mississauga, Canada, 8US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
  • Abstract Number: 1005 • ACR Convergence 2024

    Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib

    Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral

    Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
  • Abstract Number: 2566 • ACR Convergence 2024

    Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study

    andriko Palmowski1, Zhivana Boydzhieva2, Paula Hoff3, Sandra Hermann3, burkhard Muche3, David Simon4, Gerhard Krönke3, Edgar Wiebe5 and FRANK HARTMUT DR. BUTTGEREIT5, 1Charité - Universittsmedizin Berlin, Berlin, Germany, 2Charité Universittsmedizin, Berlin, Germany, 3Rheumatology, Charité, Berlin, Germany, 4Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
  • Abstract Number: 1049 • ACR Convergence 2024

    Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology

    Eric Roberts1, Gabriela Schmajuk2 and Jinoos Yazdany3, 1University of California, San Francisco, SF, CA, 2UCSF / SFVA, San Francisco, CA, 3UCSF, San Francisco, CA

    Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
  • Abstract Number: 2609 • ACR Convergence 2024

    Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry

    Eric Roberts1, Nick Bansback2, Chien-Wen Tseng3, Steve Shiboski4, Jing Li5, Gabriela Schmajuk6 and Jinoos Yazdany7, 1University of California, San Francisco, SF, CA, 2University of British Columbia, Vancouver, BC, Canada, 3University of Hawai'i John A. Burns School of Medicine, Honolulu, 4University of California, San Francisco, San Francisco, 5University of California, San Francisco, San Francisco, CA, 6UCSF / SFVA, San Francisco, CA, 7UCSF, San Francisco, CA

    Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
  • Abstract Number: 1073 • ACR Convergence 2024

    Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting

    Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA

    Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
  • Abstract Number: 1189 • ACR Convergence 2024

    Certain Dosages of Fasinumab Provides Superior Benefits over Placebo in Mitigating Osteoarthritis Symptoms Albeit at Increased Health Detriments: A Systematic Review and Meta-Analysis

    Muhammad Sohaib Khan1, Wania Moeen2, Umm E Salma Shabbar Banatwala2, Muhammad Usman2, Umar Mahmood2, Syed Ashad Ahmed Fatmi2, Syed Muhammad Muneeb Akhtar2, Hania Shahzad3, Muhammad Talal Ibrahim4, Nisar Ahmed5, Badaruddin Sahito2 and Muhammad Sohaib Asghar6, 1Dow University of Health Sciences, Karachi, Pakistan, 2Dow University of Health Sciences, Karachi, Sindh, Pakistan, 3UC Davis Health, Sacramento, CA, 4The Ohio State University Wexner Medical Center, Columbus, OH, 5Rapido’s Clinica Familiar, Chicago, 6AdventHealth, Sebring, FL

    Background/Purpose: Fasinumab, a newly developed anti-nerve growth factor monoclonal antibody, is currently under investigation for its potential to alleviate symptoms in osteoarthritis patients. This meta-analysis…
  • Abstract Number: 0742 • ACR Convergence 2023

    Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes

    Natalie McCormick1, Chio Yokose2, Na Lu3 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…
  • Abstract Number: 2529 • ACR Convergence 2023

    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Jeffrey R Curtis1, Tarun Arora2, Ye Liu3, Vanessa C. Brunetti4, Tzu-Chieh Lin4, Leslie Spangler4, Robert K. Stad4, Michele McDermott4, Brian D. Bradbury4 and Min Kim4, 1Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology